Avanir授权Concert的氘修饰右美沙芬产品，潜在交易价值2亿美元

Pharmadeals Review Pub Date : 2012-12-03 DOI:10.3833/pdr.v2012i3.1696

Heather Cartwright

{"title":"Avanir授权Concert的氘修饰右美沙芬产品，潜在交易价值2亿美元","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i3.1696","DOIUrl":null,"url":null,"abstract":"In a deal that could be worth more than US$200 M, Avanir Pharmaceuticals has licensed global rights to Concert Pharmaceuticals’ multiple deuterium-modified dextromethorphan (d-DM) products for the potential treatment of neurological and psychiatric disorders. Avanir’s sole marketed product is Nuedexta® (dextromethorphan plus quinidine sulphate), which was approved by the US FDA in 2010 for pseudobulbar affect.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i3.1696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In a deal that could be worth more than US$200 M, Avanir Pharmaceuticals has licensed global rights to Concert Pharmaceuticals’ multiple deuterium-modified dextromethorphan (d-DM) products for the potential treatment of neurological and psychiatric disorders. Avanir’s sole marketed product is Nuedexta® (dextromethorphan plus quinidine sulphate), which was approved by the US FDA in 2010 for pseudobulbar affect.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-12-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i3.1696\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i3.1696","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在一项价值可能超过2亿美元的交易中，Avanir制药公司获得了Concert制药公司多种氘修饰右美沙芬(d-DM)产品的全球授权，该产品可能用于治疗神经和精神疾病。Avanir的唯一上市产品是Nuedexta®(右美沙芬加硫酸奎尼丁)，该产品于2010年获得美国FDA批准用于假性球影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal

In a deal that could be worth more than US$200 M, Avanir Pharmaceuticals has licensed global rights to Concert Pharmaceuticals’ multiple deuterium-modified dextromethorphan (d-DM) products for the potential treatment of neurological and psychiatric disorders. Avanir’s sole marketed product is Nuedexta® (dextromethorphan plus quinidine sulphate), which was approved by the US FDA in 2010 for pseudobulbar affect.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量